Skip to content

EVOKE PHARMA, INC.: 10-K filed 2014-03-25

What EVOKE PHARMA, INC. reported in its annual report filed 2014-03-25 (fiscal FY 2013): 20 published measures, 92 facts as tagged in accession 0001193125-14-114409.

This filing

Form
10-K (annual report)
Filed
2014-03-25
Fiscal period
fiscal FY 2013
Accession
0001193125-14-114409 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All EVOKE PHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-12-3124,986,458USD
At 2012-12-31116,013USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2013-12-313,803,197USD
At 2012-12-311,550,201USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-12-3121,183,261USD
At 2012-12-31-19,659,354USD
At 2011-12-31-17,654,331USD
At 2010-12-31-15,275,792USD
At 2009-12-31-10,275,510USD
At 2008-12-31-5,133,675USD
At 2007-12-31-1,922,195USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-12-3124,196,691USD
At 2012-12-31116,013USD
At 2011-12-31865,876USD
At 2010-12-314,036,763USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-10-01 to 2013-12-31-1,616,698USD92
2013-01-01 to 2013-12-31-2,836,465USD365
2007-01-30 to 2013-12-31-22,691,468USD2528
2013-07-01 to 2013-09-30-485,904USD92
2013-04-01 to 2013-06-30-239,871USD91
2013-01-01 to 2013-03-31-493,992USD90
2012-10-01 to 2012-12-31-672,450USD92
2012-01-01 to 2012-12-31-2,017,528USD366
2012-07-01 to 2012-09-30-486,254USD92
2012-04-01 to 2012-06-30-358,666USD91
2012-01-01 to 2012-03-31-500,158USD91
2011-01-01 to 2011-12-31-2,401,244USD365
2010-01-01 to 2010-12-31-5,039,338USD365
2009-01-01 to 2009-12-31-5,159,638USD365
2008-01-01 to 2008-12-31-3,227,664USD366
2007-01-30 to 2007-12-31-2,009,591USD336

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-12-31-3,040,270USD365
2007-01-30 to 2013-12-31-22,024,236USD2528
2012-01-01 to 2012-12-31-1,749,863USD366
2011-01-01 to 2011-12-31-2,893,108USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-12-3127,120,948USD365
2007-01-30 to 2013-12-3146,220,927USD2528
2012-01-01 to 2012-12-311,000,000USD366
2011-01-01 to 2011-12-31-277,779USD365

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-01-01 to 2013-12-31145,966USD365
2007-01-30 to 2013-12-31235,677USD2528
2012-01-01 to 2012-12-3112,505USD366
2011-01-01 to 2011-12-3122,705USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-01-01 to 2013-12-31-2,601,828USD365
2007-01-30 to 2013-12-31-22,547,890USD2528
2012-01-01 to 2012-12-31-2,002,426USD366
2011-01-01 to 2011-12-31-2,414,568USD365

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-12-3124,430,953USD
At 2012-12-31116,013USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-12-312,284,906USD
At 2012-12-31570,409USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2013-01-01 to 2013-12-312,601,828USD365
2007-01-30 to 2013-12-3122,547,890USD2528
2012-01-01 to 2012-12-312,002,426USD366
2011-01-01 to 2011-12-312,414,568USD365

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-10-01 to 2013-12-31636,423USD92
2013-01-01 to 2013-12-31956,980USD365
2007-01-30 to 2013-12-3116,948,509USD2528
2013-07-01 to 2013-09-3078,731USD92
2013-04-01 to 2013-06-30130,846USD91
2013-01-01 to 2013-03-31110,981USD90
2012-10-01 to 2012-12-31318,347USD92
2012-01-01 to 2012-12-311,165,645USD366
2012-07-01 to 2012-09-30337,003USD92
2012-04-01 to 2012-06-30213,010USD91
2012-01-01 to 2012-03-31297,285USD91
2011-01-01 to 2011-12-311,844,044USD365

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-12-316,096,752shares
At 2012-12-311,242,750shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2013-12-3143,874,119USD
At 2012-12-31195,525USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2013-12-312,954,053USD
At 2012-12-31979,792USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2013-12-31555,505USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-10-01 to 2013-12-31944,359USD92
2013-01-01 to 2013-12-311,644,848USD365
2007-01-30 to 2013-12-314,949,381USD2528
2013-07-01 to 2013-09-30406,862USD92
2013-04-01 to 2013-06-3072,578USD91
2013-01-01 to 2013-03-31221,049USD90
2012-10-01 to 2012-12-31343,570USD92
2012-01-01 to 2012-12-31836,781USD366
2012-07-01 to 2012-09-30140,746USD92
2012-04-01 to 2012-06-30147,328USD91
2012-01-01 to 2012-03-31205,137USD91
2011-01-01 to 2011-12-31570,524USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2013-01-01 to 2013-12-31-234,637USD365
2007-01-30 to 2013-12-31-143,578USD2528
2012-01-01 to 2012-12-31-15,102USD366
2011-01-01 to 2011-12-3113,324USD365

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2013-01-01 to 2013-12-3125,120,948USD365
2007-01-30 to 2013-12-3125,125,528USD2528

Inspect the source

Entity
EVOKE PHARMA, INC. / CIK 0001403708
Captured
2026-09-21T17:19:23.305Z
SEC response SHA-256
1d2ea0edbbb48066d62d49983dacdd25cf55cdf81e3ee5a742e26303a1f7d06e

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001403708.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))